Mireia Margelí Vila

3.6k total citations
94 papers, 1.4k citations indexed

About

Mireia Margelí Vila is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mireia Margelí Vila has authored 94 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 46 papers in Cancer Research and 43 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mireia Margelí Vila's work include Breast Cancer Treatment Studies (35 papers), Advanced Breast Cancer Therapies (33 papers) and HER2/EGFR in Cancer Research (28 papers). Mireia Margelí Vila is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), Advanced Breast Cancer Therapies (33 papers) and HER2/EGFR in Cancer Research (28 papers). Mireia Margelí Vila collaborates with scholars based in Spain, United States and Italy. Mireia Margelí Vila's co-authors include Eudald Felip, Agustí Barnadas, Miquel Tarón, Rafael Rosell, Adrià Bernat‐Peguera, Montserrat Muñoz-Mateu, José Á. García-Sáenz, José Luís Zamora Manzano, Ignasi Tusquets and José Miguel Sánchez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mireia Margelí Vila

88 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mireia Margelí Vila Spain	20	784	485	440	416	174	94	1.4k
Laura Pizzuti Italy	23	906 1.2×	410 0.8×	454 1.0×	333 0.8×	117 0.7×	96	1.7k
Roberta Maltoni Italy	21	722 0.9×	376 0.8×	338 0.8×	299 0.7×	89 0.5×	84	1.2k
Alain Gelibter Italy	22	974 1.2×	333 0.7×	332 0.8×	574 1.4×	193 1.1×	100	1.4k
K. Gunnarsdóttir Denmark	9	774 1.0×	461 1.0×	477 1.1×	221 0.5×	84 0.5×	14	1.2k
Luisa Carbognin Italy	20	928 1.2×	320 0.7×	337 0.8×	402 1.0×	125 0.7×	67	1.3k
Henrik Hellborg Sweden	18	667 0.9×	355 0.7×	337 0.8×	293 0.7×	156 0.9×	24	1.2k
Véronique D’Hondt France	21	781 1.0×	241 0.5×	298 0.7×	335 0.8×	144 0.8×	83	1.3k
Stephen Welch Canada	24	1.0k 1.3×	279 0.6×	626 1.4×	388 0.9×	176 1.0×	124	1.9k
P. Hupperets Netherlands	21	629 0.8×	340 0.7×	328 0.7×	266 0.6×	238 1.4×	40	1.4k
Nicola Battelli Italy	23	1.0k 1.3×	553 1.1×	512 1.2×	814 2.0×	291 1.7×	91	1.9k

Countries citing papers authored by Mireia Margelí Vila

Since Specialization

Citations

This map shows the geographic impact of Mireia Margelí Vila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mireia Margelí Vila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mireia Margelí Vila more than expected).

Fields of papers citing papers by Mireia Margelí Vila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mireia Margelí Vila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mireia Margelí Vila. The network helps show where Mireia Margelí Vila may publish in the future.

Co-authorship network of co-authors of Mireia Margelí Vila

This figure shows the co-authorship network connecting the top 25 collaborators of Mireia Margelí Vila. A scholar is included among the top collaborators of Mireia Margelí Vila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mireia Margelí Vila. Mireia Margelí Vila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navarro‐Sabaté, Àurea, Rebeca Font, Josep Alfons Espinàs, et al.. (2025). Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?. Cancers. 17(2). 200–200. 1 indexed citations

Cirauqui, Beatriz, José Luis Ramírez, Vanesa García‐Barberán, et al.. (2024). Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck. 47(1). 57–67.

Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2023). 387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer. Annals of Oncology. 34. S341–S342. 1 indexed citations

Hernandez, Laura L., Aintzane Urbizu, Paula Rodríguez‐Martínez, et al.. (2023). Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer. Cancers. 15(12). 3068–3068. 6 indexed citations

Bernat‐Peguera, Adrià, et al.. (2022). Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data. The Breast. 62. 1–9. 3 indexed citations

Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458. 3 indexed citations

Lu, Yen‐Shen, J.M.Y. Chiu, Mario Airoldi, et al.. (2020). 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1. Annals of Oncology. 31. S363–S363. 3 indexed citations

Cirauqui, Beatriz, Teresa Morán, Anna Estival, et al.. (2020). Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Reports in Oncology. 13(1). 130–138. 2 indexed citations

Felip, Eudald, Clara Pérez‐Mañá, Mireia Margelí Vila, et al.. (2019). New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib – A Case Report. Breast Care. 15(5). 548–552. 6 indexed citations

10.

Morán, Teresa, Vanesa Quiroga, Beatriz Cirauqui, et al.. (2019). A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and <b><i>EGFR</i></b>-Mutant Non-Small Cell Lung Cancer. Oncology Research and Treatment. 42(3). 107–114. 6 indexed citations

11.

Blancas, Isabel, Elena Aguirre, Serafín Morales, et al.. (2018). Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. Clinical & Translational Oncology. 21(4). 459–466. 10 indexed citations

12.

Ayala, Francisco, Raquel Andrés, José Á. García-Sáenz, et al.. (2018). SEOM clinical guidelines in early stage breast cancer (2018). Clinical & Translational Oncology. 21(1). 18–30. 47 indexed citations

13.

Serra, Pere, José Sanz‐Santos, E. Castellà, et al.. (2017). Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound‐guided transbronchial needle aspiration. Cytopathology. 29(1). 35–40. 1 indexed citations

14.

Cirauqui, Beatriz, et al.. (2014). Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report. Journal of Medical Case Reports. 8(1). 6–6. 2 indexed citations

15.

Bermejo, Begoña, Amparo Ruı́z, Manuel Ruíz Borrego, et al.. (2013). Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial.. Journal of Clinical Oncology. 31(15_suppl). 1027–1027. 2 indexed citations

16.

Martín, Miguel, Pedro Sánchez‐Rovira, Montserrat Muñoz-Mateu, et al.. (2011). Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study. Annals of Oncology. 22(12). 2591–2596. 26 indexed citations

17.

Antón, Antonio, Agustí Barnadas, Jesús Florián, et al.. (2011). Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study. Clinical & Translational Oncology. 13(4). 281–286. 3 indexed citations

18.

Loi, Sherene, Rodrigo Salgado, Fanny Piette, et al.. (2011). Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT).. Journal of Clinical Oncology. 29(15_suppl). 556–556. 5 indexed citations

19.

Alba, Emilio, Manuel Ruíz‐Borrego, Mireia Margelí Vila, et al.. (2010). Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Research and Treatment. 122(1). 169–176. 58 indexed citations

20.

Ramírez, José Luis, Carme Sarries, Bárbara Roig, et al.. (2003). Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Letters. 193(2). 207–216. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact